BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
German drugmaker to use state-of-art antibody in tandem with advanced therapies to more effectively fight cancer, detect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback